Latest European Expansion News

Smart Parking Limited grew its ANPR sites by 17% in Q3 FY26 and increased parking breach notices by 19%, leveraging acquisitions and AI technology to expand across Europe and New Zealand.

Regener8 Resources has formalised its acquisition of the Srebrenica North polymetallic project in Bosnia and Herzegovina, setting the stage for a maiden exploration program targeting high-grade silver and base metals in a prolific European mining district.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Adslot Ltd achieved positive net operating cash flow in Q3 FY26 while trimming its workforce by nearly a third to sharpen focus on its Symphony and Webfirm units. The company is navigating declining marketplace revenues and preparing for a key contract renewal with Group M.

Genetic Signatures has locked in a 10-year supply deal with Denmark’s Hvidovre Hospital for its EasyScreen™ Pan-Enteric assay, marking a significant step in its European expansion. The agreement covers 28,000 tests in the first year with growth expected, leveraging the company’s proprietary 3base® technology to streamline complex gastrointestinal pathogen detection.

Redivium Limited advances its recapitalisation efforts and project development despite ASX suspension, withdrawing its European Green Bond and exploring new UK site options.

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

DTI Group Ltd reported a 33% revenue increase to $5.69 million for the half-year ending December 2025, significantly narrowing its net loss while winning major contracts with Rio Tinto and CAF. The company’s strategic re-entry into Europe and a robust $175 million opportunity pipeline signal a promising outlook.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

International Graphite Limited has reported pilot-scale testwork results exceeding purity targets for expandable graphite, underpinning plans for a European production facility.